RTW Biotech Opportunities Ltd (LSE: RTWG), a London-listed investment fund focused on biopharmaceutical and medical technology assets, announced on 18 November 2026 that it repurchased 106,811 of its Ordinary Shares at a price of $2.44 per share on 17 November 2026. The repurchased shares will be held in treasury and will carry no voting rights. The buyback was conducted under authority granted by shareholders at the company's Annual General Meeting in June 2026, with Jefferies International Limited acting as broker for the transaction.
Key Points
- RTW Biotech Opportunities Ltd (LSE: RTWG) — a healthcare-focused closed-ended investment fund managed by RTW Investments, LP
- The company repurchased 106,811 Ordinary Shares at $2.44 per share on 17 November 2026, with shares to be held in treasury
- Total voting rights now stand at 317,189,823 following settlement; 28,777,617 shares are held in treasury with no voting rights
- Investors should watch for further buyback activity under the June 2026 AGM authority, which remains in effect until the 2027 AGM or earlier revocation
RTW Biotech's 17 November Share Repurchase: Price, Volume and Treasury Allocation
The company confirmed the purchase of 106,811 Ordinary Shares at $2.44 per share, executed on 17 November 2026. All repurchased shares will be held in treasury rather than cancelled, in line with the company's stated current intention. Treasury shares attract no voting rights, meaning they are excluded from the total voting rights calculation. The announcement states that the company is prohibited from paying a price that would represent a premium to net asset value for any shares acquired under this buyback programme, providing a structural constraint on the repurchase price.
Post-Buyback Share Capital: 317,189,823 Voting Rights and 28,777,617 Treasury Shares
Following the purchase and settlement of the 106,811 shares, RTW Biotech Opportunities Ltd's total issued Ordinary Share capital stands at 345,967,440. Of this figure, 28,777,617 shares are now held in treasury and carry no voting rights. The resulting total voting rights in the company amount to 317,189,823. The announcement confirms that shareholders may use this figure of 317,189,823 as the denominator when calculating whether they are required to disclose interests or changes in interests under the FCA's Disclosure and Transparency Rules.
June 2026 AGM Authority Permits Repurchase of Up to 14.99% of Ordinary Shares
The buyback is being conducted under authority granted at the company's Annual General Meeting in June 2026, which permits RTW Biotech Opportunities Ltd to repurchase a maximum of 14.99% of its Ordinary Shares. The authority remains valid until a new shareholder mandate is granted — expected at the 2027 AGM — or until it is expressly revoked by shareholders. The announcement notes that the actual number of shares repurchased will depend on prevailing market conditions, and Jefferies International Limited has been instructed as broker for the programme in accordance with FCA Listing Rules.



Please wait processing your request...